plus a chance to lead the ILT2 field. The companies already wrapped up a phase 1 dose-escalation study weighing BND-22 as a monotherapy and in combination with Keytruda, plus Eli Lilly and Merck ...

Preclinical studies have demonstrated that BND-22 exerts broad anti-tumor effects by disrupting ILT2-mediated "do not eat me" signals in macrophages and activating NK and CD8+ lymphocytes.